Inhalation formulations of 1'-cyano substituted carbocyclic nucleoside analogs
By developing inhaled drug formulations containing compounds of formula I, Ia, or Ib, the problem of drug delivery that directly targets the respiratory tract in existing technologies has been solved, achieving highly efficient treatment and prevention of viral infections while avoiding systemic side effects.
Patent Information
- Application Number
- CN202180025157.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-03-12
- Filing Date
- 2021-04-05
- Publication Date
- 2026-01-09
- Estimated Expiration
- 2041-04-05
AI Technical Summary
There is a lack of effective vaccines or treatment modalities to prevent or treat infections caused by viruses of the Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, and Paramyxoviridae families. Existing treatments mainly rely on supportive therapy, and there is a lack of drug delivery technologies that directly target the respiratory tract.
Provides inhaled drug formulations containing compounds of formula I, Ia, or Ib and their pharmaceutically acceptable salts and aqueous solvents, delivering the drug directly to the affected respiratory tract via inhalation, achieving high local drug concentrations and avoiding systemic dilution and metabolism.
This allows drugs to be directly targeted to the respiratory tract, achieving high local concentrations, reducing systemic side effects, and providing effective treatment and prevention for viral infections.